Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells

@article{Araki2013NegligibleIO,
  title={Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells},
  author={R. Araki and M. Uda and Y. Hoki and Misato Sunayama and Miki Nakamura and S. Ando and M. Sugiura and H. Ideno and A. Shimada and A. Nifuji and M. Abe},
  journal={Nature},
  year={2013},
  volume={494},
  pages={100-104}
}
The advantages of using induced pluripotent stem cells (iPSCs) instead of embryonic stem (ES) cells in regenerative medicine centre around circumventing concerns about the ethics of using ES cells and the likelihood of immune rejection of ES-cell-derived tissues. However, partial reprogramming and genetic instabilities in iPSCs could elicit immune responses in transplant recipients even when iPSC-derived differentiated cells are transplanted. iPSCs are first differentiated into specific types… Expand
The immunogenicity of cells derived from induced pluripotent stem cells
  • Xuemei Fu
  • Biology, Medicine
  • Cellular and Molecular Immunology
  • 2014
The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives
Cells derived from iPSC can be immunogenic — Yes or No?
Reduced Immunogenicity of Induced Pluripotent Stem Cells Derived from Sertoli Cells
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
Immunogenicity of induced pluripotent stem cells.
iPS cells produce viable mice through tetraploid complementation
Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury
...
1
2
3
4
5
...